M. Maruszczak

A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK

R. Nicholas, N. Adlard, S. Montgomery, 2017, Journal of medical economics.

Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada

Yi Qian, D. Boyne, W. Cheung, 2022, Oncology and Therapy.

Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom.

N. Adlard, S. Montgomery, M. Maruszczak, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England

N. Bergvall, N. Adlard, S. Montgomery, 2015, Journal of medical economics.

The who-choice cost-effectiveness Threshold: a Country-level analysis of changes over time

M. Maruszczak, J. Kusel, M. Griffiths, 2015 .

A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK

R. Nicholas, N. Adlard, S. Montgomery, 2017, Journal of medical economics.